6-bromomethyl-3'-trifluoromethyl[2,2']bipyridinyl-5-carboxylic acid ethyl ester | 794592-24-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-bromomethyl-3'-trifluoromethyl[2,2']bipyridinyl-5-carboxylic acid ethyl ester
• 英文别名: Ethyl 2-(bromomethyl)-6-[3-(trifluoromethyl)pyridin-2-yl]pyridine-3-carboxylate
• CAS: 794592-24-8
• 化学式: C₁₅H₁₂BrF₃N₂O₂
• 分子量: 389.172
• InChiKey: QNDQWIYNDUYTHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-bromomethyl-3'-trifluoromethyl[2,2']bipyridinyl-5-carboxylic acid ethyl ester 在 肼 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 2-(3-trifluoromethyl-2-pyridinyl)pyrido[2,3-d]pyridazin-5-one
  参考文献：
  名称：

  [EN] SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS
  [FR] 1-PHTALAZINAMINES SUBSTITUEES EN TANT QU'ANTAGONISTES DE VR-1

  摘要：

  本发明提供了一种化合物，其化学式为（I）：其中Ar和R1为苯基或杂环芳基，R2通常为氢，R3为氢或烷基，X、Y和Z通常为CH或N，作为VR-1拮抗剂；或其药学上可接受的盐；包含它的药物组合物；其在治疗中的用途；用于制造治疗疼痛或炎症的药物的用途；以及治疗疼痛或炎症的方法。

  公开号：

  WO2004099177A1
• 作为产物：
  描述：

  6-methyl-3'-trifluoromethyl[2,2']bipyridinyl-5-carboxylic acidethyl ester 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 4.0h， 以905 mg的产率得到6-bromomethyl-3'-trifluoromethyl[2,2']bipyridinyl-5-carboxylic acid ethyl ester
  参考文献：
  名称：

  Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists

  摘要：

  The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) is a nonselective cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation in an attempt to identify novel agents for pain treatment. The design and synthesis of a series of novel TRPV1 antagonists with a variety of different 6,6-heterocyclic cores is described, and an extensive evaluation of the pharmacological and pharmacokinetic properties of a number of these compounds is reported. For example, the 1,8-naphthyridine 52 was characterized as an orally bioavailable and brain penetrant TRPV1 antagonist. In vivo, 52 fully reversed carrageenan-induced thermal hyperalgesia (CITH) in rats and dose-dependently potently reduced complete Freund's adjuvant (CFA) induced chronic inflammatory pain after oral administration.

  DOI：

  10.1021/jm100051g

文献信息

• [EN] SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS<br/>[FR] 1-PHTALAZINAMINES SUBSTITUEES EN TANT QU'ANTAGONISTES DE VR-1
  申请人：MERCK SHARP & DOHME

  公开号：WO2004099177A1

  公开（公告）日：2004-11-18

  The present invention provides a compound of formula (I): in which Ar and R1 are phenyl or a heteroaromatic group, R2 is generally hydrogen, R3 is hydrogen or alkyl and X, Y and Z are generally CH or N as VR-1 antagonists; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in therapy; use of it to manufacture medicaments to treat pain or inflammation; and methods of treating pain or inflammation.

  本发明提供了一种化合物，其化学式为（I）：其中Ar和R1为苯基或杂环芳基，R2通常为氢，R3为氢或烷基，X、Y和Z通常为CH或N，作为VR-1拮抗剂；或其药学上可接受的盐；包含它的药物组合物；其在治疗中的用途；用于制造治疗疼痛或炎症的药物的用途；以及治疗疼痛或炎症的方法。
• Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists
  作者：Charles A. Blum、Timothy Caldwell、Xiaozhang Zheng、Rajagopal Bakthavatchalam、Scott Capitosti、Harry Brielmann、Stéphane De Lombaert、Mark T. Kershaw、David Matson、James E. Krause、Daniel Cortright、Marci Crandall、William J. Martin、Beth Ann Murphy、Susan Boyce、A. Brian Jones、Glenn Mason、Wayne Rycroft、Helen Perrett、Rachael Conley、Nicola Burnaby-Davies、Bertrand L. Chenard、Kevin J. Hodgetts

  DOI：10.1021/jm100051g

  日期：2010.4.22

  The transient receptor potential cation channel, subfamily V, member 1 (TRPV1) is a nonselective cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation in an attempt to identify novel agents for pain treatment. The design and synthesis of a series of novel TRPV1 antagonists with a variety of different 6,6-heterocyclic cores is described, and an extensive evaluation of the pharmacological and pharmacokinetic properties of a number of these compounds is reported. For example, the 1,8-naphthyridine 52 was characterized as an orally bioavailable and brain penetrant TRPV1 antagonist. In vivo, 52 fully reversed carrageenan-induced thermal hyperalgesia (CITH) in rats and dose-dependently potently reduced complete Freund's adjuvant (CFA) induced chronic inflammatory pain after oral administration.